---
title: Seizure Prophylaxis in the Neurocritical Care Unit
author: Nikhil Patel
date: '2021-08-07'
slug: seizure-prophylaxis
categories:
tags: []
subtitle: ''
excerpt: ''
series: ~
layout: single
bibliography: [../../../static/references/bib.bib]
csl: [../../../static/references/nikhil.csl]
link-citations: true
---

<script src="{{< blogdown/postref >}}index_files/header-attrs/header-attrs.js"></script>


<p>Due to the risk of seizures in various neurological disease states, the use of seizure prophylaxis is a common yet controversial practice.</p>
<p>Incidence of seizures varies greatly, depending on the disease state, location affected, and interventions performed.</p>
<div id="intracerebral-tumors" class="section level2">
<h2>Intracerebral Tumors</h2>
<p>Seizures are common in this population. Can be the presenting symptom in 40% of patients, 20-45% develop seizures during the course of their disease.<span class="citation"><sup><a href="#ref-vincentHemodynamicMonitoringSupport2021" role="doc-biblioref">1</a></sup></span></p>
<p>More likely in the setting primary brain tumor vs metastatic, low-grade vs high-grade glioma, and certain specific tumor types.</p>
<p>AAN practice parameter in 2000 concluded that seizure prophylaxis is not effective in these patients based on 12 studies (4 of which were randomized trials).</p>
<p>Many harms were found (as many as 42% of patients had some adverse effect).</p>
<div id="references" class="section level3 unnumbered">
<h3>References</h3>
<div id="refs" class="references csl-bib-body">
<div id="ref-vincentHemodynamicMonitoringSupport2021" class="csl-entry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Vincent JL, Joosten A, Saugel B. Hemodynamic <span>Monitoring</span> and <span>Support</span>. <em>Critical Care Medicine</em>. 2021. doi:<a href="https://doi.org/10.1097/CCM.0000000000005213">10.1097/CCM.0000000000005213</a></div>
</div>
</div>
</div>
</div>
